中国P站

Short-chain fatty acids; Gut microbiome; Metabolism; Inflammation; Gut-brain axis; Neurological disorders; Cancer; Immune responses; Cardiovascular health; Epigenetics

Introduction

Short-chain fatty acids (SCFAs) play a critical role in mediating the complex interactions between the gut microbiome, immunity, and the central nervous system. This review highlights their profound influence on gut barrier integrity, inflammation, and neuroinflammation, firmly establishing SCFAs as key modulators in the intricate gut-brain axis communication and identifying them as potential therapeutic targets for various related conditions [1].

SCFAs are crucial in regulating host metabolism, significantly influencing aspects like energy homeostasis, glucose tolerance, and insulin sensitivity. This paper thoroughly explores their vital role in the initial development and subsequent progression of metabolic syndrome, offering valuable insights into potential therapeutic strategies that could target either SCFA production or their specific signaling pathways to mitigate disease [2].

SCFAs are central to the complex communication between the gut microbiota and the host, actively influencing numerous physiological processes, including robust immune responses and efficient energy metabolism. This comprehensive review deeply delves into their intricate mechanisms of action, specifically highlighting their remarkable potential in effectively modulating inflammation and diligently maintaining gut homeostasis, which is essential for overall health [3].

The gut microbiota-derived SCFAs significantly impact both the development and progression of cancer. This insightful article discusses the crucial dual role of SCFAs, observing their capacity to either inhibit or actively promote tumor growth, a dynamic outcome that depends profoundly on the specific cancer type and the concentration of SCFAs present. This positions them as promising potential therapeutic agents or reliable biomarkers in the field of oncology [4].

This study investigates the intricate relationship between SCFAs, the precise composition of the gut microbiota, and the overall severity of COVID-19. It suggests that specific alterations in SCFA profiles might play a significant role in disease prognosis and could indeed represent a novel therapeutic target for effectively managing COVID-19-related complications by strategically modulating the delicate gut environment [5].

SCFAs are rapidly emerging as crucial regulators of vital immune responses and systemic inflammation, carrying significant implications for the management of various systemic autoimmune diseases. This comprehensive review thoughtfully discusses how SCFAs meticulously modulate inflammatory pathways and enhance gut barrier function, thereby offering promising potential therapeutic avenues for challenging conditions like rheumatoid arthritis and lupus [6].

The complex interplay between gut microbiota-derived SCFAs and a range of neurological disorders is increasingly recognized and understood. This compelling article explores in detail how SCFAs profoundly impact critical brain function, neuroinflammation, and neurodegeneration, strongly suggesting their substantial potential as effective therapeutic targets for debilitating conditions like Parkinson's disease, Alzheimer's, and multiple sclerosis [7].

SCFAs significantly influence host gene expression through sophisticated epigenetic mechanisms, thereby modulating various critical physiological processes, including metabolism, immunity, and essential brain function. This thorough review highlights their pivotal role in effectively shaping the intricate host-microbiota interplay and offers a deeper, more nuanced understanding of their substantial therapeutic potential in both metabolic and neurological diseases [8].

The impact of gut microbiota-derived SCFAs on overall cardiovascular health is a rapidly expanding and critically important area of research. This comprehensive review systematically analyzes their precise mechanisms of action in regulating crucial physiological parameters such as blood pressure, lipid metabolism, and inflammatory responses, strongly suggesting their promising potential as innovative therapeutic targets for a variety of cardiovascular diseases [9].

SCFAs play a significant and multifaceted role in glucose and lipid metabolism, consequently offering considerable therapeutic potential for effective diabetes management. This insightful article examines how SCFAs precisely influence insulin sensitivity, enhance pancreatic β-cell function, and optimize energy expenditure, highlighting their considerable utility in developing novel and targeted strategies against type 2 diabetes [10].

Description

Short-chain fatty acids (SCFAs) are increasingly recognized as pivotal mediators in the complex communication network between the gut microbiota and the host, underpinning numerous vital physiological processes. These potent compounds play a critical role in shaping the gut-brain axis, where they influence gut barrier integrity, modulate inflammatory responses, and impact neuroinflammation. This suggests SCFAs are key modulators in this crucial communication pathway and represent potential therapeutic targets for neurological and gut-related disorders. Their influence on brain function, neuroinflammation, and neurodegeneration is particularly evident, making them relevant for conditions like Parkinson's, Alzheimer's, and multiple sclerosis [1, 3, 7].

Furthermore, SCFAs are instrumental in regulating host metabolism, with significant implications for energy homeostasis, glucose tolerance, and insulin sensitivity. Their active involvement is observed in the development and progression of metabolic syndrome, providing valuable insights into novel therapeutic strategies focused on SCFA production or signaling pathways. Beyond this, SCFAs offer considerable therapeutic potential for comprehensive diabetes management. Research carefully examines how these fatty acids precisely influence insulin sensitivity, support robust pancreatic β-cell function, and optimize overall energy expenditure, highlighting their utility in developing novel and effective strategies against type 2 diabetes [2, 10].

The regulatory power of SCFAs extends significantly to immune responses and inflammation, which holds profound implications for systemic autoimmune diseases. Reviews specifically discuss the precise mechanisms by which SCFAs modulate inflammatory pathways and enhance gut barrier function. This area of research offers promising new therapeutic avenues for challenging conditions such as rheumatoid arthritis and lupus, indicating a broad systemic impact on immune system regulation [6].

A specific and critical area of investigation involves the gut microbiota-derived SCFAs and their significant impact on cancer development and progression. Studies reveal a complex dual role, where SCFAs can either inhibit or actively promote tumor growth, a dynamic outcome largely dependent on the specific cancer type and concentration. This positions SCFAs as promising potential therapeutic agents or valuable biomarkers in the field of oncology. Additionally, recent studies have unveiled an intricate relationship between SCFAs, gut microbiota composition, and the severity of COVID-19. Alterations in SCFA profiles are suggested to play a role in disease prognosis and could present a novel therapeutic target for managing COVID-19-related complications through targeted modulation of the gut environment [4, 5].

Finally, the broader systemic impacts of SCFAs are continuously being uncovered, including their profound influence on host gene expression through intricate epigenetic mechanisms. This modulation affects a spectrum of physiological processes, encompassing metabolism, immunity, and essential brain function, deepening our understanding of the host-microbiota interplay and offering therapeutic potential in various diseases. Concurrently, the impact of gut microbiota-derived SCFAs on cardiovascular health constitutes a rapidly expanding and crucial area of research. Systematic analyses reveal their mechanisms in regulating blood pressure, lipid metabolism, and inflammatory responses, underscoring their potential as innovative therapeutic targets for cardiovascular diseases [8, 9].

Conclusion

Short-chain fatty acids (SCFAs) emerge as pivotal regulators in numerous physiological systems, mediating critical interactions between the gut microbiome and host health. These fatty acids profoundly influence the gut-brain axis, playing a significant role in maintaining gut barrier integrity, modulating inflammation, and impacting neuroinflammation, suggesting their potential as therapeutic targets for central nervous system disorders. Beyond neural implications, SCFAs are crucial for host metabolism, affecting energy homeostasis, glucose tolerance, and insulin sensitivity. This makes them key modulators in the development and progression of metabolic syndrome and offering new strategies for diabetes management. Their influence extends to immune responses, where they modulate inflammatory pathways, which is critical for systemic autoimmune diseases. SCFAs facilitate extensive microbiota-host crosstalk, influencing processes from immune function to energy metabolism and maintaining overall gut homeostasis. Furthermore, research reveals a complex role for SCFAs in cancer, where they can either inhibit or promote tumor growth, depending on the context, thus identifying them as potential therapeutic agents or biomarkers. Recent studies have also connected alterations in SCFA profiles to COVID-19 severity, suggesting their role in prognosis and as a potential therapeutic target. SCFAs are recognized for their impact on cardiovascular health by regulating blood pressure, lipid metabolism, and inflammatory responses. They also influence host gene expression via epigenetic mechanisms, shaping the microbiota-host interplay in metabolism and neurological conditions. This broad spectrum of influence underscores SCFAs' fundamental role in health and disease.

References

1. Min S, Wenhui W, Zhi L (2023) .Commun Biol 6:636.

   , ,

2. Yan G, Hong W, Mingyuan G (2022) .Front Endocrinol (Lausanne) 13:935544.

   , ,

3. Pei-Yun C, Le H, Xiaoxi S (2021) .Gut Microbes 13:1935619.

   , ,

4. Jing Y, Lin W, Qingling J (2023) .Gut Microbes 14:2261771.

   , ,

5. Qing Y, Danning H, Xiaojie W (2022) .Gut Microbes 14:2011030.

   , ,

6. Ting Z, Yingjie L, Jingxian L (2023) .Int J Mol Sci 24:8530.

   , ,

7. José MS, André FA, Silvânia FM (2021) .Int J Neurosci 131:1109-1126.

   , ,

8. Rian MS, Marvellous vdW, Gerard C (2020) .Gut Microbes 11:1-13.

   , ,

9. Cheng H, Xiaohan Z, Shuhua D (2023) .Nutrients 15:2901.

   , ,

10. Can M, Chao B, Le Z (2021) .Front Cell Dev Biol 9:624128.

    , ,